Claim Missing Document
Check
Articles

Found 23 Documents
Search

DRUG THERAPY IN PATIENTS WITH GRADE 4 DEXTRA HIP OSTEOARTHRITIS WITH COMORBID HYPERTENSION AND TYPE 2 DIABETES MELLITUS Astiani, Rangki; Piter, Piter; Anggraeni, Ria; Luthfiana, Farisa; Sari, Dini Permata; Ramatillah, Diana Laila; Khan, Khasif
SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL Vol 10, No 2 (2025)
Publisher : Universitas 17 Agustus 1945 Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52447/scpij.v10i2.8977

Abstract

Osteoarthritis (OA) is a chronic degenerative disease that affects the joints, especially heavy joints such as the knees and hips. OA often causes chronic pain and limited mobility, which is even more complex when accompanied by comorbid hypertension and type 2 diabetes mellitus. These comorbidities increase the risk of pharmacotherapy side effects and drug interactions, requiring a multidisciplinary approach and careful clinical pharmacy monitoring. The purpose of this report is to review the pharmacotherapy management of grade 4 OA Hip Dextra with comorbid HT and DMT2, assessing the safety, effectiveness, and role of clinical pharmacists in therapy optimization. A retrospective case study was conducted by analyzing the patient's medical records, including anamnesis, physical examination, laboratory, pharmacological therapy, and clinical response. The analysis was conducted based on the national guidelines of the Indonesian Ministry of Health, the 2021 National Formulary, PERKENI 2023, and PAPDI 2021. The patient was given combination therapy of NSAIDs, analgesics, prophylactic antibiotics, muscle relaxants, gastric protection, and supplementation for anemia. Therapeutic adjustments were made according to the patient's response and laboratory parameters. Clinical pharmacy monitoring ensures pain control, mobility, hemoglobin, and blood sugar. A multidisciplinary approach based on national guidelines has been shown to improve the safety and effectiveness of OA therapy with multiple comorbidities.
Studi Potensi Interaksi Obat pada Pasien Diabetes Melitus Tipe-2 di Rumah Sakit Islam Jakarta Cempaka Putih Panjaitan, Katrin Olivia; Handayani, Widya; Sari, Dini Permata; Dyanto, Norman
Educatoria : Jurnal Ilmiah Ilmu Pendidikan Vol. 6 No. 2 (2026): April (In Progress)
Publisher : Lembaga Pendidikan, Penelitian, dan Pengabdian Kamandanu

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36312/educatoria.v6i2.1117

Abstract

This study aims to determine the demographic characteristics, description of potential drug interactions, and the relationship between demographics and number of drugs with potential drug interactions in patients with Type-2 Diabetes Mellitus in the Outpatient Installation of Jakarta Islamic Hospital Cempaka Putih. This study is an analytical observational study with a retrospective cross-sectional design with a total sampling of 200 prescriptions from January-March 2025. The sampling technique used total sampling, so that all prescriptions that met the research criteria were included as samples. Identification of interactions was carried out theoretically using the medscape drug interaction checker and drugs.com interactions checker, then analyzed descriptively and Chi-Square test with a 95% confidence level (α = 0.05). The results showed that patients were predominantly aged 56-65 years (44.5%) and >65 years (32.5%) with a relatively balanced gender distribution. Potential drug interactions were found in 61.0% of prescriptions, with moderate interactions (84.2%), major (10.5%), and minor (5.3%) predominating in severity. The most common type of interaction was pharmacodynamic (54.4%). Statistical tests showed that age (p=0.542) and gender (p>0.05) were not significantly associated with potential drug interactions, while the number of medications in the prescription was significantly associated (p<0.05). Thus, the potential for drug interactions in patients with Type 2 Diabetes Mellitus is more influenced by the complexity and number of medications used than demographic factors.
IDENTIFIKASI ADVERSE DRUG REACTION (ADR) OBAT ANTI TUBERKULOSIS PADA PASIEN TB DI RSUD PASAR REBO JAKARTA TIMUR Sari, Dini Permata; Silitonga, Julita; Luthfiana, Farisa; Anggraeni, Ria
JIFI (Jurnal Ilmiah Farmasi Imelda) Vol. 9 No. 2 (2026): JIFI (Jurnal Ilmiah Farmasi Imelda)
Publisher : Universitas Imelda Medan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52943/jifarmasi.v9i2.2044

Abstract

Tuberculosis (TB) remains a major public health problem in Indonesia, ranking second globally in TB burden. Although Anti-Tuberculosis Drugs (ATDs) are effective in curing TB, prolonged treatment and combination regimens may lead to Adverse Drug Reactions (ADRs), potentially affecting patient adherence and treatment outcomes. This study aimed to identify the types of ADRs experienced by TB patients undergoing ATD therapy at Pasar Rebo General Hospital, East Jakarta, and to analyze the relationship between age, gender, and duration of drug use with ADR occurrence. This research employed a descriptive-analytic retrospective design conducted from June to July 2025. A total of 60 adult TB patients receiving first-line ATD therapy (Isoniazid, Rifampicin, Pyrazinamide, and Ethambutol) were included. Data were collected using questionnaires and analyzed using univariate and multivariate statistical methods with SPSS. Causality assessment of ADRs was performed using the Naranjo algorithm. The results showed that 88.33% of patients experienced ADRs. The most frequently reported symptoms were nausea (48.33%), rash/itching (28.33%), and joint pain (26.67%). Most ADRs were categorized as “Probable” based on the Naranjo score. Multivariate analysis revealed that gender was significantly associated with ADR occurrence (p = 0.041), while age and duration of drug use were not statistically significant. In conclusion, ADRs are common among TB patients receiving ATD therapy, with gastrointestinal and dermatological symptoms being the most prevalent. Gender appears to be an important predictor of ADR risk. Therefore, close clinical monitoring and gender-sensitive pharmacovigilance strategies are essential to ensure patient safety, improve adherence, and optimize TB treatment outcomes.